Criteria for Abstract Submission

• Abstracts must focus on scientific questions, clinical observations, or primary scientific data.
• To minimize commercial bias, abstracts must not include company logos, names, or proprietary drug names.
• Only the first author may submit requests. Submissions from co-authors, or medical communication / PR companies will not be considered.
• First authors may submit up to two abstracts. If both are accepted, an alternate presenter must be appointed for one of the posters.
• No revisions to abstracts will be allowed after the submission deadline.
​​​​​​​• Abstracts will be reviewed by the IO360° Poster Review Committee, with selection notifications sent by January 24, 2025, including for late-breaking submissions.

​​​​​​
Late-Breaking Submission Criteria

Late-breaking submissions are allowed if they meet one of the following criteria:

• Results from large-scale phase II or III trials not available by the main deadline (December 6, 2024).
• Groundbreaking findings that could significantly impact current practices.

To submit late-breaking data, provide a placeholder abstract by December 6, 2024, including:
​​​​​​​
•  All authors and their disclosures
• Background and methods sections
• Main clinical endpoint for your analysis
• Type of analysis, planned analysis date, and statistical methods


Submission Requirements
​​​​​​​
• Author Information: List full names, degrees, institutions, locations, and email addresses for all authors. The first author will receive all future correspondence. Up to 20 authors per abstract.

• Research Identification: Indicate if your abstract reports on original research or a clinical trial. For clinical trials, if already registered, provide the registry name and trial number. Registration is not required for submission but may be necessary by law for publication.

• Funding & Disclosures: Specify the funding source for the abstract, including any secondary sources. All authors must disclose financial ties with for-profit healthcare companies, which will be included in the meeting materials.

• Abstract Title and Content: Provide a title that doesn’t reveal the study’s results or conclusions. Include background, methods, results, and conclusions in a PDF (max 2700 characters), with one data table (up to 12 rows) and no figures or illustrations. Title edits may be suggested by the IO360° Poster Review Committee.
​​​​​​​
• Drug Name Usage: Use only generic drug names in your abstract. If only a brand name is available, you may include it, but omit trademark symbols.